Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07578584 | A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity | PHASE1 | RECRUITING | 146 | — | — | May 7, 2026 | Feb 18, 2028 | Jun 4, 2026 | 1 | Germany |
Measured in events
| Arm | Type | Description |
|---|---|---|
| SAD | EXPERIMENTAL | Participants will receive NNC0497-0040 or placebo matched to NNC0497-0040 subcutaneously. |
| MAD1 | EXPERIMENTAL | Participants will receive NNC0497-0040 or placebo matched to NNC0497-0040 subcutaneously. |
| MAD2 | EXPERIMENTAL | Participants will receive NNC0497-0040 or placebo matched to NNC0497-0040 subcutaneously. |
| MAD3 | EXPERIMENTAL | Participants will receive NNC0497-0040 or placebo matched to NNC0497-0040 subcutaneously. |
| MAD4 | EXPERIMENTAL | Participants will receive NNC0497-0040 or placebo matched to NNC0497-0040 subcutaneously. |
| Name | Type | Description |
|---|---|---|
| NNC0497-0040 | DRUG | NNC0497-0040 will be administered subcutaneously. |
| Placebo | DRUG | Placebo will be administered subcutaneously. |
For SAD cohorts Inclusion Criteria: * Female of non-childbearing potential or male aged 18-55 years (both inclusive) at screening. * Body mass index between 18.5 kilogram per m\^2 and 29.9 kilogram per m\^2 (both inclusive) at screening. * Considered to be generally healthy based on the medical hi...